Genome Editing Market Emerging Trend, Opportunities, Key Players, Huge Growth, Revenue Analysis, 2023-2035
The development of novel therapeutic modalities that target diseases at the genetic level have prompted the pharmaceutical industry to research and develop cost-effective, safe and efficient genome editing technologies.
The global genome editing market size is estimated to grow from USD 3.90 billion in 2024 to USD 14.5 billion by 2035, representing a CAGR of 12.6% during the forecast period till 2035.
To know more about the report visit https://www.rootsanalysis.com/....reports/genome-editi
The human genome is estimated to comprise of close to three billion nucleotide base pairs, featuring approximately 20,000-25,000 protein-coding regions, or genes. These genes / gene sequences act as a code which regulates or controls the synthesis of proteins, hence, controlling gene expression. Over the years, advances in the field of genome editing have enabled researchers to process large volumes of genetic data and thereby, develop an in-depth understanding of its impact on the fundamental biological processes and the development of certain diseases. The Human Genome Project, which was initiated in 1990 helped the researchers to gather extensive insights into the genetic profile of nearly 5,000 human disease conditions identified till date.
Further, recent advances in the field of gene research industry have enabled medical researchers to modify the human genome expression through certain techniques, popularly known as genome editing or genome engineering. Genome editing is a technique used to modify a single gene or a set of genes within the genome of an organism by altering the nucleotide sequence, using specialized molecular tools, such as artificially engineered nucleases or molecular scissors. Moreover, the need for genome editing at the desired site in the genome has resulted in the exploration of various genome editing tools that are being developed by gene editing companies; these include zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) and CRISPR technique. These genome editing tools have been extensively used as corrective strategies to treat the clinical conditions which develop as a result of genetic abnormalities, such as sickle cell disease, Parkinson’s disease, hearing loss, peripheral artery disease, spinal muscular atrophy, autoimmune diseases, and other genetic disorders.
In addition, these genome editing tools hold a promise to expand the ability to explore and alter any genome, as well as constitute a new and promising paradigm to understand the underlying cause of the associated disease. Moreover, in the last decade, CRISPR technique has created a significant impact on both basic and applied biological research. However, careful considerations have to be made while incorporating any genome editing tool for therapeutic intervention in order to ensure its efficiency, precision, safety and targeted delivery in the cells. Moreover, owing to the advancements in genome editing technologies, the reliability on the gene editing companies having the expertise in this domain has upsurged. This will eventually aid the drug developers (gene therapy and cell therapy developers) to address the challenges in effective delivery of genome editing tools and improve the clinical outcome of the therapeutics by achieving the desired genetic manipulation.
A steady growth in the partnership activity has been observed in recent years; technology licensing agreements have been the most prominent type of partnership model adopted by players based in the US.
During our research, we came across several partnerships that have been established by various gene editing companies engaged in the genome editing market (technologies), since 2018. Amongst all the partnership models, technology licensing agreements (52%) emerged as the most preferred type of partnership model adopted by industry stakeholders engaged in the genome editing technologies domain. Notable examples of technology licensing agreements include (in reverse chronological order, international agreements inked in 2023) the agreements signed between Bayer and Acuitas Therapeutics (June 2023), ERS Genomics and Applied Biological Materials (June 2023), and Life Edit Technologies and Novo Nordisk (May 2023). Other key focus areas for partnerships inked by gene editing companies include research and development, technology integration, and mergers and acquisitions.
Thank you for reading our report. Kindly get in touch with us to know more about the report or to receive a customized copy of it. Our team will ensure the report is tailored according to your needs.
To get a sample of the report visit https://www.rootsanalysis.com/....reports/genome-editi
